Biomotion Sciences Ordinary Shares (SLXN )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol SLXN
- Company Biomotion Sciences Ordinary Shares
- Price $0.33
- Changes Percentage 45.33
- Change 0.1039
- Day Low $0.28
- Day High $0.47
- Year High $13.56
- Year Low $0.21
- Market Cap $4,805,906
- Price Avg 50 EMA (D) $0.48
- Price Avg 200 EMA (D) $7.86
- Exchange NASDAQ
- Volume 199,238,828
- Average Volume 2,802,242
- Open $0.38
- Previous Close $0.23
- EPS -1.64
- PE -0.20
- Earnings Announcement 2024-11-27 12:00:00
- Shares Outstanding $14,427,816
Company brief: BIOMOTION SCIENCES ORDINARY SHARES (SLXN )
- Healthcare
- Biotechnology
- Mr. Ilan Hadar M.B.A.
- https://silexion.com
- IL
- N/A
- 04-07-2021
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.